Clinician perspectives on current issues in lung cancer drug development

Saiama N. Waqar; Philip D. Bonomi; Ramaswamy Govindan; Fred R. Hirsch; Gregory J. Riely; Vassiliki Papadimitrakopoulou; Dickran Kazandjian; Sean Khozin; Erin Larkins; Dane J. Dickson; Shakun Malik; Leora Horn; Andrea Ferris; Alice T. Shaw; Pasi A. Jänne; Tony S.K. Mok; Roy Herbst; Patricia Keegan; Richard Pazdur; Gideon M. Blumenthal

doi:10.1016/j.jtho.2016.05.009

Clinician perspectives on current issues in lung cancer drug development

Saiama N. Waqar, Philip D. Bonomi, Ramaswamy Govindan, Fred R. Hirsch, Gregory J. Riely, Vassiliki Papadimitrakopoulou, Dickran Kazandjian, Sean Khozin, Erin Larkins, Dane J. Dickson, Shakun Malik, Leora Horn, Andrea Ferris, Alice T. Shaw, Pasi A. Jänne, Tony S.K. Mok, Roy Herbst, Patricia Keegan, Richard Pazdur, Gideon M. Blumenthal

Research output: Contribution to journal › Review article › peer-review

7 Scopus citations

Abstract

Recent advances in molecularly targeted therapy and immunotherapy offer a glimmer of hope for potentially realizing the dream of personalized therapy for lung cancer. This article highlights current questions in clinical trial design, enrollment strategies and patient focused drug development, with particular emphasis on unique issues in trials of targeted therapy and immunotherapy. Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.

Original language	English
Pages (from-to)	1387-1396
Number of pages	10
Journal	Journal of Thoracic Oncology
Volume	11
Issue number	9
DOIs	https://doi.org/10.1016/j.jtho.2016.05.009
State	Published - 2016

Keywords

Clinical trials
Immunotherapy
Lung cancer
Targeted therapy

Access to Document

10.1016/j.jtho.2016.05.009

Cite this

Waqar, S. N., Bonomi, P. D., Govindan, R., Hirsch, F. R., Riely, G. J., Papadimitrakopoulou, V., Kazandjian, D., Khozin, S., Larkins, E., Dickson, D. J., Malik, S., Horn, L., Ferris, A., Shaw, A. T., Jänne, P. A., Mok, T. S. K., Herbst, R., Keegan, P., Pazdur, R., & Blumenthal, G. M. (2016). Clinician perspectives on current issues in lung cancer drug development. Journal of Thoracic Oncology, 11(9), 1387-1396. https://doi.org/10.1016/j.jtho.2016.05.009

@article{cfcc64e8fbfe44d4b3d6788561ae8613,

title = "Clinician perspectives on current issues in lung cancer drug development",

abstract = "Recent advances in molecularly targeted therapy and immunotherapy offer a glimmer of hope for potentially realizing the dream of personalized therapy for lung cancer. This article highlights current questions in clinical trial design, enrollment strategies and patient focused drug development, with particular emphasis on unique issues in trials of targeted therapy and immunotherapy. Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.",

keywords = "Clinical trials, Immunotherapy, Lung cancer, Targeted therapy",

author = "Waqar, {Saiama N.} and Bonomi, {Philip D.} and Ramaswamy Govindan and Hirsch, {Fred R.} and Riely, {Gregory J.} and Vassiliki Papadimitrakopoulou and Dickran Kazandjian and Sean Khozin and Erin Larkins and Dickson, {Dane J.} and Shakun Malik and Leora Horn and Andrea Ferris and Shaw, {Alice T.} and J{\"a}nne, {Pasi A.} and Mok, {Tony S.K.} and Roy Herbst and Patricia Keegan and Richard Pazdur and Blumenthal, {Gideon M.}",

year = "2016",

doi = "10.1016/j.jtho.2016.05.009",

language = "English",

volume = "11",

pages = "1387--1396",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

number = "9",

}

Waqar, SN, Bonomi, PD, Govindan, R, Hirsch, FR, Riely, GJ, Papadimitrakopoulou, V, Kazandjian, D, Khozin, S, Larkins, E, Dickson, DJ, Malik, S, Horn, L, Ferris, A, Shaw, AT, Jänne, PA, Mok, TSK, Herbst, R, Keegan, P, Pazdur, R & Blumenthal, GM 2016, 'Clinician perspectives on current issues in lung cancer drug development', Journal of Thoracic Oncology, vol. 11, no. 9, pp. 1387-1396. https://doi.org/10.1016/j.jtho.2016.05.009

TY - JOUR

T1 - Clinician perspectives on current issues in lung cancer drug development

AU - Waqar, Saiama N.

AU - Bonomi, Philip D.

AU - Govindan, Ramaswamy

AU - Hirsch, Fred R.

AU - Riely, Gregory J.

AU - Papadimitrakopoulou, Vassiliki

AU - Kazandjian, Dickran

AU - Khozin, Sean

AU - Larkins, Erin

AU - Dickson, Dane J.

AU - Malik, Shakun

AU - Horn, Leora

AU - Ferris, Andrea

AU - Shaw, Alice T.

AU - Jänne, Pasi A.

AU - Mok, Tony S.K.

AU - Herbst, Roy

AU - Keegan, Patricia

AU - Pazdur, Richard

AU - Blumenthal, Gideon M.

PY - 2016

Y1 - 2016

N2 - Recent advances in molecularly targeted therapy and immunotherapy offer a glimmer of hope for potentially realizing the dream of personalized therapy for lung cancer. This article highlights current questions in clinical trial design, enrollment strategies and patient focused drug development, with particular emphasis on unique issues in trials of targeted therapy and immunotherapy. Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.

AB - Recent advances in molecularly targeted therapy and immunotherapy offer a glimmer of hope for potentially realizing the dream of personalized therapy for lung cancer. This article highlights current questions in clinical trial design, enrollment strategies and patient focused drug development, with particular emphasis on unique issues in trials of targeted therapy and immunotherapy. Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.

KW - Clinical trials

KW - Immunotherapy

KW - Lung cancer

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84987811330&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2016.05.009

DO - 10.1016/j.jtho.2016.05.009

M3 - Review article

C2 - 27401214

AN - SCOPUS:84987811330

SN - 1556-0864

VL - 11

SP - 1387

EP - 1396

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 9

ER -

Clinician perspectives on current issues in lung cancer drug development

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this